364793-93-1 Usage
General Description
4-[(6-bromopyridin-3-yl)methyl]morpholine is a chemical compound with the molecular formula C11H14BrN2O. It is a morpholine derivative with a bromopyridine moiety attached to the morpholine ring. 4-[(6-bromopyridin-3-yl)methyl]morpholine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has the potential to act as a building block in the creation of various organic compounds, owing to the presence of the morpholine and bromopyridine functional groups, which allow for diverse chemical reactions and applications. Additionally, it possesses a high degree of reactivity and can undergo substitution, addition, and other synthetic transformations to yield a wide range of valuable products in the fields of medicine and agriculture.
Check Digit Verification of cas no
The CAS Registry Mumber 364793-93-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,4,7,9 and 3 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 364793-93:
(8*3)+(7*6)+(6*4)+(5*7)+(4*9)+(3*3)+(2*9)+(1*3)=191
191 % 10 = 1
So 364793-93-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H13BrN2O/c11-10-2-1-9(7-12-10)8-13-3-5-14-6-4-13/h1-2,7H,3-6,8H2
364793-93-1Relevant articles and documents
HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
-
Paragraph 0735, (2016/05/02)
The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE
-
Page/Page column 37; 38, (2014/09/29)
The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R1, R2, R3, R4, R5, X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.
4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors
Zhang, Nan,Wu, Biqi,Boschelli, Diane H.,Golas, Jennifer M.,Boschelli, Frank
scheme or table, p. 5071 - 5074 (2010/03/24)
A series of 4-anilino-7-pyridyl-3-quinolinecarbonitriles was prepared as Src kinase inhibitors. A systematic SAR study of substitutions on both the pyridine ring and the 3-quinolinecarbonitrile core established the requirements for optimal activity. The l
